Zetao Liao

Zetao Liao

Auto-generated profile, based on publicly available information

Zetao Liao

Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
QLQing Lv
Qing Lv
YJYutong Jiang
Yutong Jiang
JQJun Qi
Jun Qi
YZYanli Zhang
Yanli Zhang
XZXi Zhang
Xi Zhang
ZLZhi Ming Lin
Zhi Ming Lin
Background: China has a large population; however, medical resources are unevenly distributed and extremely limited, and more medical services are needed. With the development and ever-increasing popularity of mobile internet communication, China has created a mode of mobile health (mHealth) care to resolve this problem. Objective: The aim of this study was (1) to describe the problems associated with China’s medical care practice, (2) explore the need for and the feasibility of internet-based medical care in China, and (3) analyze the functionality of and services offered by internet-based health care platforms for the management of chronic diseases. Methods: Data search was performed by searching national websites, the popular search engine Baidu, the App Store, and websites of internet medical care institutions, using search terms like “mobile health,” “Internet health,” “mobile medical,” “Internet medical,” “digital medical,” “digital health,” and “online doctor.” A total of 6 mobile apps and websites with the biggest enrollment targeting doctors and end users with chronic diseases in China were selected. Results: We recognized the limitations of medical and health care providers and unequal distribution of medical resources in China. An mHealth care platform is a novel and efficient way for doctors and patients to follow up and manage chronic diseases. Services offered by these platforms include reservation and payment, medical consultation, medical education assessment, pharmaceutical and medical instruments sales, electronic medical records, and chronic disease management. China’s health policies are now strongly promoting the implementation of mHealth solutions, particularly in response to the increasing burden of chronic diseases and aging in the population. Conclusions: China's internet-based medical and health care mode can benefit the populace by providing people with high-quality medical resources. This can help other countries and regions with high population density and unevenly distributed medical resources manage their health care concerns.

20 February 2023 in Arthritis Care & Research
Verified
Journal Article
Closed access
ZLZetao Liao
Zetao Liao
JCJun Chang
Jun Chang
ZZZhaohua Zhu
Zhaohua Zhu
WHWeiyu Han
Weiyu Han
TMTao Meng
Tao Meng
CDChanghai Ding
Changhai Ding

3 December 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YJYutong Jiang
Yutong Jiang
QLQing Lv
Qing Lv
SRShaoqi Rao
Shaoqi Rao
ZLZetao Liao
Zetao Liao
PZPingping Zhang
Pingping Zhang
JGJieruo Gu
Jieruo Gu
Introduction. Familial aggregation of ankylosing spondylitis (AS) has been frequently noticed. However, the mode of inheritance in AS remains poorly understood. Our aim was to determine the mode of inheritance best fitting the observed transmission pattern of AS families. Methods. Families with 5 or more AS patients diagnosed with 1984 modified New York criteria were recruited. We performed complex segregation analysis for a binary trait in regressive multivariate logistic models. The inheritance models, including sporadic, major gene, environmental, general, and other 9 models, were compared by likelihood ratio tests and Akaike’s Information Criterion. Results. This research included 9 Chinese Han AS families with a total number of 315 persons, including 74 patients. First, familial association was determined. Sporadic with familial association model was rejected when compared with either the general model or the homogeneous general model (p<0.001). The environmental model was also rejected when compared with general models (p<0.02). Mendelian dominate mode fitted best in 5 AS families, while Tau AB free model best explained the mode of inheritance in these AS families. Conclusion. This study provided evidence in support of Mendelian dominant mode and firstly discovered a non-Mendelian mode called tau AB free inheritance mode in AS.

1 June 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LFL. Fang
L. Fang
YPYunfeng Pan
Yunfeng Pan
XGX. Guo
X. Guo
ZLZ. Liao
Z. Liao
ZLZ. Lin
Z. Lin
JGJun Gu
Jun Gu
Background The prevalence rate of hepatitis B virus (HBV) infection in China (13%) and many other developing countries are much higher than that in developed countries. When anti-TNF agents are more available and affordable in developing countries, the safety of anti-TNF therapy in terms of the reactivation of hepatitis B virus (HBV) infection need more concern. Very few data from a prospective study focus on the use of TNF antagonists in patients with concurrent ankylosing spondylitis (AS) and HBV infection are available by now. Objectives To evaluate the influence of etanercept on the reactivation of HBV infection in HBsAg carriers with AS. Methods In this 48 weeks observation, HBsAg carriers with active AS (BASDAI ≥ 4 ) despite failed treatment with at least two NSAIDs and sulfasalazine (for patients with persistent peripheral arthritis) were studied. Patients must have normal liver function prior to etanercept therapy. All patients received the treatment of etanercept 50mg each week. For patients who had positive HBV load (>100 copy/ml) at baseline, lamivudin were prescribed preventively. Pre-existing NSAIDs and sulfasalazine were allowed. During the study, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and HBV load (polymerase chain reaction) were monitored every 6 weeks in the first 12 weeks and every 12 weeks after week 12. Increased AST/ALT and HBV load were managed and monitored according to expert opinion. After withdraw of etanercept due to any reason, monitoring of ALT, AST and HBV load must be conducted until normal result was obtained in 2 consecutive tests. Results Twenty-four patients (22 male, 1 female) were recruited. At baseline, seventeen patients (group 1, including 1 female) had normal viral load (<100 copy/ml), other 7 patients (group 2, with preventive lamivudin) had abnormal viral load (2.9e3, 2.9e6, 4.7e4, 1.7e4, 3.6e6, 5.8e7, 7.8e4 copy/ml, respectively). Two patients from group 1 and one patient from group 2 discontinued etanercept at week 12 due to ineffectiveness. Reactivation of hepatitis B occurred in one patient from group 1, and another from group 2. The patient from group 1 had mild elevated ALT and AST (59 and 76 IU/L, respectively) and increased HBV load (4.6e3) at Week 12. After prescription of Entecavir, abnormal laboratory finding was monitored every 4 weeks, both liver enzyme and viral load decreased to normal range in 8 weeks and remained normal. The patient from group 2 (baseline viral load 3.6e6) had mild elevated ALT and AST (72 and 79 IU/L, respectively) and increased HBV load (7.2e8) at week 24. After prescription of Adefovir (combined with the pre-existing Lamivudin), both liver enzyme and viral load decreased to normal range in 12 weeks and remained normal. For the rest 22 patients, no significant elevated AST/ALT or increased viral load was seen during the 48 weeks follow-up. Conclusions Etanercept therapy represent a safe and effective option for HBsAg carriers with AS refractory to traditional treatment. Prophylaxis strategy with more effective anti-viral drugs is recommended to reduce the risk of hepatitis B reactivation. Disclosure of Interest None Declared

6 March 2018 in JMIR Preprints
Verified
Preprint
Open access
QLQing Lv
Qing Lv
YJYutong Jiang
Yutong Jiang
JQJun Qi
Jun Qi
YZYanli Zhang
Yanli Zhang
XZXi Zhang
Xi Zhang
ZLZhi Ming Lin
Zhi Ming Lin
BACKGROUND China has a large population; however, medical resources are unevenly distributed and extremely limited, and more medical services are needed. With the development and ever-increasing popularity of mobile internet communication, China has created a mode of mobile health (mHealth) care to resolve this problem. OBJECTIVE The aim of this study was (1) to describe the problems associated with China’s medical care practice, (2) explore the need for and the feasibility of internet-based medical care in China, and (3) analyze the functionality of and services offered by internet-based health care platforms for the management of chronic diseases. METHODS Data search was performed by searching national websites, the popular search engine Baidu, the App Store, and websites of internet medical care institutions, using search terms like “mobile health,” “Internet health,” “mobile medical,” “Internet medical,” “digital medical,” “digital health,” and “online doctor.” A total of 6 mobile apps and websites with the biggest enrollment targeting doctors and end users with chronic diseases in China were selected. RESULTS We recognized the limitations of medical and health care providers and unequal distribution of medical resources in China. An mHealth care platform is a novel and efficient way for doctors and patients to follow up and manage chronic diseases. Services offered by these platforms include reservation and payment, medical consultation, medical education assessment, pharmaceutical and medical instruments sales, electronic medical records, and chronic disease management. China’s health policies are now strongly promoting the implementation of mHealth solutions, particularly in response to the increasing burden of chronic diseases and aging in the population. CONCLUSIONS China's internet-based medical and health care mode can benefit the populace by providing people with high-quality medical resources. This can help other countries and regions with high population density and unevenly distributed medical resources manage their health care concerns.